Abbott Labs (ABT) – ABT has been a relative strength Healthcare name the past week after holding its 55 EMA last month. The stock has begun December on a bullish note so ideally waiting for a dip to the 8 ema or retest of monthly value near 130 is optimal for a new entry. Most names that are at 52 week highs during a weaker sluggish market will tend to outperform once the broad market firms up. ABT has stronger seasonality starting to work in its favor also with bullish bias the last 10 years in December, January and February. 8 of the last 10 years were up in December with average returns of 1.5% and 2.3% in Jan and Feb. For a lower beta stock that performs well in a risk off market these are solid 10 year average returns. ABT is up 21% YTD but breaking out to fresh all time highs shows leadership during a weak market and likely sees continuation from this multi month expansion. During its more recent pullback in early October, the stock saw buyers step in near YTD VPOC at 118 and a confirmed bullish TTM squeeze firing off in the past week can push the stock into the 135-140 zone the next few months. ABT has a large call buy in open interest still from a buyer on 10/20 when the June 2022 $115 calls were bought for over $4.1M in premium.